Galecto

Galecto PP&E per Employee

Delisted·Sep 22, 2026

The PP&E per Employee of Galecto (GLTO) as of Oct 30, 2026 is 51,000.00 USD. In the previous year, PP&E per Employee was 148,142.86 USD — a change of -65.57% (lower).

PP&E per Employee

51,000.00USD

YoY

-65.57%

Last updated:

PP&E per Employee of Galecto is 2022 51,000.00 USD. PP&E per Employee of Galecto was 2021 148,142.86 USD. It decreases by -65.57% lower compared to the previous year.

The Galecto PP&E per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PP&E per Employee
Date
PP&E per Employee
Jan 1, 2019
42,571.43 USD
Jan 1, 2020
126,428.57 USD
Jan 1, 2021
148,142.86 USD
Jan 1, 2022
51,000.00 USD
The Galecto PP&E per Employee history
YEARPP&E per EmployeeYoY
51,000.00USD-65.57%
148,142.86USD+17.18%
126,428.57USD+196.98%
42,571.43USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Galecto Stock analysis

What does Galecto do? Galecto, Inc. develops small molecule therapeutics targeting galectin-3 and LOXL2 for cancer and fibrotic diseases. The company focuses on GB0139 for Idiopathic Pulmonary Fibrosis (IPF), GB1211 for oncology and liver cirrhosis, and GB2064 for myelofibrosis. These products are designed to address biological processes central to these conditions. The firm targets medical professionals and healthcare institutions seeking novel treatments for fibrotic and oncological disorders. Galecto's revenue streams come from the development and potential future commercialization of its therapeutic candidates. The company is a clinical-stage biotechnology firm, meaning it is currently in the development phase and has not yet generated revenue from product sales. The primary buyers of Galecto's products will be healthcare providers and pharmaceutical distributors once the drugs are approved and marketed. The company's product pipeline includes GB0139 for IPF, GB1211 for oncology and liver cirrhosis, and GB2064 for myelofibrosis. These products are developed as small molecule inhibitors targeting specific biological processes. Galecto's focus on clinical-stage development indicates that it is still in the research and testing phase, with no current revenue from product sales. Galecto is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Galecto stock

PP&E per Employee of Galecto is 51,000.00 USD in 2022.

PP&E per Employee of Galecto changed from 148,142.86 USD to 51,000.00 USD, representing a -65.57% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of PP&E per Employee Galecto since 2006 – with annual values, charts, and detailed analysis.

PP&E per employee measures the physical capital intensity per worker. Higher values indicate more capital-intensive operations.

PP&E per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track PP&E per Employee's Galecto historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Galecto

All Key Metrics — Galecto